Informace o publikaci

Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology

Autoři	FELICIANI C. JOLY P. JONKMAN M.F. ZAMBRUNO G. ZILLIKENS D. IOANNIDES D. KOWALEWSKI C. JEDLIČKOVÁ Hana KARPATI S. MARINOVIC B. MIMOUNI D. UZUN S. YAYLI S. HERTL M. BORRADORI L.
Rok publikování	2015
Druh	Článek v odborném periodiku
Časopis / Zdroj	British Journal of Dermatology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1111/bjd.13717
Obor	Ostatní lékařské obory
Klíčová slova	LINKED-IMMUNOSORBENT-ASSAY; INDIRECT IMMUNOFLUORESCENCE; TOPICAL CORTICOSTEROIDS; MYCOPHENOLATE-MOFETIL; PLASMA-EXCHANGE; DIAGNOSIS; DISEASES; MULTICENTER; AZATHIOPRINE; ACQUISITA
Popis	Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients, bullae may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. Our consensus for the treatment of bullous pemphigoid has been developed under the guidance of the European Dermatology Forum in collaboration with the European Academy of Dermatology and Venereology. It summarizes evidence-based and expert-based recommendations.